https://www.selleckchem.com/products/sb-3ct.html
The incidence rate of esophageal fistulas was 30.1%. The median OS for patients with esophageal fistula was only 6.9 (95%[CI]=6.0-7.8) months. The risk for developing esophageal fistulas was significantly high for ulcerative-type tumors (odds ratio [OR]=3.202; 95%[CI]=1.036-7.850, P=0.011) and for those invading the bronchus/trachea (OR=3.378; 95%[CI]=1.223-9.332, P=0.048). We demonstrated that CRT for T4b ESCC patients has a curative potential, despite a high incidence of esophageal fistula, which was the main cause of treatment failure
Like
Comment
Share
